Rising medicinal use On 1 July, 2023, the Therapeutic Products Administration amended its scheduling of copyright substances to enable the prescription of psilocybin for use in copyright assisted psychotherapy for procedure-resistant despair. Trials as for their usefulness and protection in dealing with numerous psychiatric circumstances are ongoi